Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper describes the development of diagnostic criteria for several enduring sexual dysfunction conditions following the use of certain medications, highlighting common sexual and non-sexual symptoms.

This paper introduces a framework attributing Post-SSRI, Post-Finasteride, Post-Retinoid, and an unnamed sexual dysfunction syndrome to downregulated estrogen receptor activity, potentially guiding future treatments in sexual medicine.

This review discusses post-SSRI sexual dysfunction syndrome and highlights its significant clinical and regulatory implications, but reports no new findings.

This policy brief reports that post-drug syndromes like Post-Finasteride Syndrome are largely overlooked in current pharmacovigilance systems, which prioritize acute drug reactions, resulting in inadequate recognition and management of persistent medication-induced conditions.

This policy brief highlights that post-drug syndromes remain under-recognized in pharmacovigilance, leading to inadequate risk assessments and patient care. It identifies systemic failures in current frameworks and recommends actions to improve long-term drug safety monitoring and education, affecting public health outcomes significantly.

This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions.

Antidepressants can cause long-term side effects like severe withdrawal symptoms and sexual dysfunction, which can last for months or years after stopping the medication.

This study observed enduring sexual dysfunction reported in 300 cases globally following the use of SSRIs, finasteride, and isotretinoin, with common symptoms like genital anaesthesia and loss of libido.

This review identifies evidence of sexual adverse effects, particularly linked to finasteride, in men using systemic dermatologic medications but reports no new clinical findings.

The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.

This review discusses various treatments for hair loss, such as topical agents, oral minoxidil, and laser therapies, but reports no new clinical results; debates on issues like post-finasteride syndrome are also covered.

This article discusses androgenetic alopecia in men and reports that finasteride at 1 mg/day for 24 months is generally well tolerated and may effectively inhibit hair loss.

Oral retinoids can cause side effects ranging from mild to severe, including birth defects, and require careful monitoring and contraception.

This review discusses the roles of androgens and estrogens in skin functions and disorders, and highlights the use of estrogen-progestin treatments and anti-androgens in managing hirsutism and acne, without reporting new results.

Acne can appear or persist in adulthood due to hormonal changes, external factors, or substance use, and requires appropriate treatment.

This review discusses various forms of ichthyosis, including genetic and acquired types, detailing their characteristics, causes, and potential management strategies, but reports no new clinical results.

This review discusses the distinct clinical and psychological aspects of adult female acne and reports no new clinical results, highlighting the need for a comprehensive management approach.

This analysis examines acne vulgaris using an integrative approach, highlighting its links with psychopathology, lifestyle, and diet, but reports no new results.

This review traces the historical understanding and treatment of acne across ancient Egyptian, Greek, and Roman civilizations, but provides no new clinical findings.

This review discusses the role of hormonal dysregulation and metabolic syndrome in hidradenitis suppurativa and reports no new clinical results.

This article discusses nutritional contributions to hair health and highlights the need for identifying risk factors for deficiencies but reports no new clinical findings.

In this study, dutasteride was found to be effective and safe in treating androgenetic alopecia in men who did not respond to finasteride, with improvements observed in hair loss and quality over 24 weeks.

This review examines hair and skin disorders in post-menopausal women and notes a lack of evidence supporting specific treatments for this population.

This review found no evidence that DHEA improves quality of life or decreases menopausal symptoms in peri- and postmenopausal women, but it may slightly enhance sexual function compared to placebo.

This study discusses the potential of topical retinoids, vitamin A derivatives, to improve treatment outcomes for androgenetic alopecia by promoting hair growth through extending the anagen phase and stimulating follicular activity, offering a promising approach when combined with existing therapies.

This review discusses medications used in dermatology, detailing their side effects and interactions, and reports no new clinical results.

This article reviews the complications and health risks associated with polycystic ovary syndrome and reports no new clinical findings.

This review discusses the role of sex hormones in cardiac hypertrophy and notes that estrogen provides protection against hypertrophy in pre-menopausal women, which is reduced after menopause but partially restored with estrogen therapy.

Different types of hair loss in dogs and cats have various causes and treatments, with outcomes ranging from good to uncertain.

This review discusses the current understanding of polycystic ovary syndrome, focusing on its epidemiology, pathophysiology, diagnosis, management, and future research directions, but reports no new clinical results.